This preferential tonic block of GluN2D subtypes is shared by all uncompetitive NMDAR antagonists, although the more potent antagonists, such as racemic ketamine and esketamine, lack selectivity for tonically and pathologically hyperactive GluN2D subtypes at doses in clinical use for MDD. The gene discussed is GRIN2D; the disease is major depressive disorder.